Mesenchymal Stem Cell Therapy, Allografts, and Bone Substitutes for Orthopedic Applications
Customize your policy alerts
Sign up for all Premera Bluecross policy alerts
Know when Premera Bluecross releases new policies or updates existing guidance.
Monitor payer policy activity
This policy addresses coverage for mesenchymal stem cell therapies and certain allograft or synthetic bone graft products used in orthopedic applications.
In 2013, allograft bone containing viable stem cells was designated investigational.
In 2015, bone graft substitutes requiring autologous blood or bone marrow aspirate were designated investigational.
An out-of-network-facility statement was removed.
CPT code 1095T was added.
CPT codes 0263T, 0264T, 0265T, and 38241 were removed.
In 2024, the policy clarified its scope for bone matrix products not involving stem cell use.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.